# Value Picks: Uncovering Hidden Investment Gems

Newsy: Value Investor Weekly
Published: 2025-10-15T19:33:00.309Z
Source: https://newsyai.com/edition/b810a3cc-76aa-43e5-88f3-a435300b2fd6
Archive: https://newsyai.com/newsy/5bbbadf7-1e6d-4c85-a79b-15b39036f33d.md

---

# Value Investor’s Deep-Dive (October 15, 2025)

> A research-first scan of 10 candidates, followed by a full valuation on the most compelling idea today. No hype—just numbers, drivers, and risks.

---

## Shortlist: 10 Value Candidates Worth Attention

1) Verizon (VZ)  
- Why now: Healthy free cash flow (FCF) and rising 2025 guidance after network investments; dividend support looks solid. ([verizon.com](https://www.verizon.com/about/news/verizon-raises-financial-guidance-adjusted-ebitda-adjusted-eps-and-free-cash-flow?utm_source=openai))

2) Pfizer (PFE)  
- Why now: Post-COVID reset largely digested; 2025 guidance suggests margin rebuild amid cost cuts; valuation depressed vs. history. ([pfizer.com](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-full-year-2025-guidance-and-reaffirms-full?utm_source=openai))

3) Medtronic (MDT)  
- Why now: Improving margin and FCF, 48th straight dividend hike, and planned diabetes separation to simplify the story. ([news.medtronic.com](https://news.medtronic.com/2025-05-21-Medtronic-reports-strong-finish-to-its-fiscal-year-with-its-fourth-quarter-financial-results-announces-dividend-increase?utm_source=openai))

4) CVS Health (CVS)  
- Why now: Pharmacy/benefits cash engine with managed-care headwinds being reset (premium deficiency reserve recognized). Multiple remains subdued. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-SECOND-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx?utm_source=openai))

5) Intel (INTC)  
- Why now: High-risk turnaround; 18A ramp and U.S. fab progress are real but require flawless execution and foundry wins. Deep value if it works. ([barrons.com](https://www.barrons.com/articles/intel-stock-price-panther-lake-chip-news-65d96fe2?utm_source=openai))

6) Micron (MU)  
- Why now: Memory upcycle and HBM demand; strong margin/FCF inflection through FY25. Cyclical—value depends on mid-cycle normalized earnings. ([investors.micron.com](https://investors.micron.com/news-releases/news-release-details/micron-technology-inc-reports-results-third-quarter-fiscal-2025?utm_source=openai))

7) Berkshire Hathaway (BRK.B)  
- Why now: Fortress balance sheet and optionality; not “cheap,” but quality at a fair price with record cash. ([nasdaq.com](https://www.nasdaq.com/articles/berkshire-hathaway-q2-earnings-revenues-decline-year-over-year?utm_source=openai))

8) Alphabet (GOOGL)  
- Why now: Low- to mid-teens P/E for a dominant franchise; capex surge weighs on near-term FCF but builds durable AI infrastructure. ([cnbc.com](https://www.cnbc.com/2025/02/04/alphabet-expects-to-invest-about-75-billion-in-capex-in-2025.html?utm_source=openai))

9) Meta (META)  
- Why now: Strong FCF and engagement; capex heavy, but ROI could be high if AI bet pays. Not a classic “deep value,” more “quality compounder at a reasonable price.” ([reuters.com](https://www.reuters.com/business/meta-commits-15-billion-ai-data-center-texas-2025-10-15/?utm_source=openai))

10) Cardinal Health (CAH)  
- Why now: Durable pharma distribution economics, growing specialty exposure, improving medical profitability, and visible EPS/FCF outlook. Valuation still below peers on many metrics. ([newsroom.cardinalhealth.com](https://newsroom.cardinalhealth.com/2025-08-12-Cardinal-Health-Reports-Fourth-Quarter-and-Fiscal-Year-2025-Results-and-Raises-Fiscal-Year-2026-Guidance?utm_source=openai))

---

## Pick: Cardinal Health (CAH)

I’m selecting Cardinal Health as the best value candidate today. It offers:

- Predictable cash flows from scale distribution
- Expanding specialty platforms (GI Alliance stake, oncology services) with higher margins
- Strengthening medical segment execution
- Clear guidance for FY26 EPS and FCF
- Still-reasonable multiples vs. direct peers McKesson and Cencora

At today’s price of $155.78, market cap ~$37B (using ~239M diluted shares guided for FY26). That sets the stage for a clean, conservative valuation. ([newsroom.cardinalhealth.com](https://newsroom.cardinalhealth.com/2025-08-12-Cardinal-Health-Reports-Fourth-Quarter-and-Fiscal-Year-2025-Results-and-Raises-Fiscal-Year-2026-Guidance?utm_source=openai))

---

## Business Snapshot

- Core: U.S. pharma distribution (brand and specialty), plus medical products and logistics (GMPD) and “Other” (at-Home Solutions, Nuclear/Precision Health, OptiFreight).  
- 2025–2026 road map: Push deeper into specialty (GI Alliance majority stake; ION), scale at-Home Solutions and logistics, drive medical profitability, and return more cash via buybacks.  
- FY25/FY26 visibility:  
  - FY25 EPS raised to $8.05–$8.15; FY26 EPS raised to $9.30–$9.50 (13–15% growth).  
  - FY26 adjusted FCF targeted at $2.75–$3.25B; capex ~$600M; buybacks ~$750M.  
  - Shares guided: ~238–240M. ([newsroom.cardinalhealth.com](https://newsroom.cardinalhealth.com/2025-05-01-Cardinal-Health-Reports-Third-Quarter-Fiscal-Year-2025-Results-and-Raises-Fiscal-Year-2025-Outlook?submitted=1&utm_source=openai))

Competitive landscape: Oligopoly with McKesson and Cencora—scale, working-capital velocity, and purchasing leverage matter most. Specialty mix and services add incremental margin. GLP‑1s shift mix but flow through the channel; distributors earn pennies on the dollar of gross billings, so volume and product complexity matter more than unit price. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cardinal-health-forecasts-annual-profit-higher-end-prior-range-2025-01-14/?utm_source=openai))

---

## What Can Go Wrong (Key Risks)

- Contract churn/renegotiations can ding segment profit even when revenue optics are flat.  
- GLP‑1 and biosimilar dynamics can change mix; execution in medical must hold.  
- Narrow margins require tight operations; small errors can matter.  
- Interest expense and working-capital swings can move near-term FCF. ([newsroom.cardinalhealth.com](https://newsroom.cardinalhealth.com/2025-05-01-Cardinal-Health-Reports-Third-Quarter-Fiscal-Year-2025-Results-and-Raises-Fiscal-Year-2025-Outlook?submitted=1&utm_source=openai))

---

## Valuation Deep-Dive

### 1) Ground-up DCF (all numbers in $ billions unless noted)

Starting point and base facts (management-guided where available):  
- FY26 non-GAAP EPS: $9.40 midpoint on ~239M shares ⇒ ~$2.25B non-GAAP net income proxy.  
- FY26 adjusted FCF: $2.75–$3.25B; we use $3.0B midpoint as Year 1 FCF.  
- Capital intensity low; capex guided ~$0.6B; working capital generally modestly positive over a cycle. ([newsroom.cardinalhealth.com](https://newsroom.cardinalhealth.com/2025-08-12-Cardinal-Health-Reports-Fourth-Quarter-and-Fiscal-Year-2025-Results-and-Raises-Fiscal-Year-2026-Guidance?utm_source=openai))

Assumptions (explicit and conservative):  
- Year 1 (FY26) FCF: $3.0B (management midpoint).  
- FCF growth years 2–5: 5.0% CAGR (mix shift to specialty, execution in medical, modest buybacks).  
- Years 6–10: 3.0% CAGR (matures with U.S. drug-spend growth near nominal GDP + specialty).  
- Terminal growth (G): 2.0% (below nominal GDP).  
- Discount rate (WACC): 8.5% base; test 8.0–9.5% in sensitivity.  
- Net debt/other: Use FCF-based equity valuation; management targets ~neutral working-cap effects over cycle. (For a conservative tilt, we haircut terminal value via higher WACC in downside case.)

Step-by-step:

- Years 1–5 FCF (B):  
  - Y1: 3.00  
  - Y2: 3.15  
  - Y3: 3.31  
  - Y4: 3.48  
  - Y5: 3.65

- Years 6–10 FCF at 3% growth:  
  - Y6: 3.76  
  - Y7: 3.87  
  - Y8: 3.99  
  - Y9: 4.11  
  - Y10: 4.23

- Terminal value at end of Y10 (Gordon): TV = FCF10 × (1+G)/(WACC–G)  
  - TV = 4.23 × 1.02 / (0.085 – 0.02) ≈ 4.31 / 0.065 ≈ 66.3

- Present value at 8.5%:  
  - PV of Y1–Y10 FCF ≈ 22.9  
  - PV of TV ≈ 29.9  
  - Enterprise value (FCF to equity) ≈ 52.8

- Equity per share (239M shares): ≈ $221 per share.

Sensitivity (per-share equity value):  
- WACC 8.0%, G 2.0% ⇒ ~$240  
- WACC 9.0%, G 1.75% ⇒ ~$200  
- WACC 9.5%, G 1.5% ⇒ ~$182

DCF fair value range (rounded): **$180–$240**, base case ≈ **$220**.

Cross-check vs. guidance: The model anchors on management’s FY26 FCF midpoint and assumes mid-single-digit growth—reasonable given specialty growth and operating discipline. ([newsroom.cardinalhealth.com](https://newsroom.cardinalhealth.com/2025-08-12-Cardinal-Health-Reports-Fourth-Quarter-and-Fiscal-Year-2025-Results-and-Raises-Fiscal-Year-2026-Guidance?utm_source=openai))

### 2) Comparables (quick and clean)

- Peers: McKesson (MCK), Cencora (COR). At today’s prices, market is granting premium multiples to the best-executing distributors; CAH trades at a discount on forward P/E using FY26 EPS ($9.30–$9.50).  
  - CAH forward P/E ≈ 16.4–16.8x at $155.78.  
  - Peer premiums reflect mix and execution, but CAH’s improving trajectory and higher FCF conversion argue for multiple convergence. 

- EV/FCF lens: FY26 FCF midpoint $3.0B on ~$37B market cap implies an ~8% FCF yield—attractive for an oligopoly distributor with visible growth. ([newsroom.cardinalhealth.com](https://newsroom.cardinalhealth.com/2025-08-12-Cardinal-Health-Reports-Fourth-Quarter-and-Fiscal-Year-2025-Results-and-Raises-Fiscal-Year-2026-Guidance?utm_source=openai))

---

## Investment View

- Thesis: CAH’s distribution moat + rising specialty/services + improving medical execution = resilient and growing FCF.  
- Valuation: DCF base ~$220 per share; downside (higher WACC/lower terminal) ~$180; upside with faster specialty growth or additional buybacks ~$240+.  
- Margin of safety: At $155–$160, the setup offers roughly 15–40% upside to fair value, plus a modest dividend.  
- What would change my mind: Major customer loss, unexpected margin compression in medical, or a reversal in specialty growth.

Bottom line: **Buy** for long-term value investors willing to own a steady FCF compounder with an improving mix and credible FY26 targets.

---

## Why Other Candidates Didn’t Win Today

- Verizon: Solid FCF guidance and dividend, but secular growth is lower; upside less compelling than CAH’s rerating potential. ([verizon.com](https://www.verizon.com/about/news/verizon-raises-financial-guidance-adjusted-ebitda-adjusted-eps-and-free-cash-flow?utm_source=openai))  
- Pfizer: Pipeline and margin rebuild are real, but headline risk remains high; need more proof of durable non-COVID growth. ([pfizer.com](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-full-year-2025-guidance-and-reaffirms-full?utm_source=openai))  
- Medtronic: Attractive, but diabetes separation execution risk and slower top-line vs. CAH’s specialty acceleration. ([news.medtronic.com](https://news.medtronic.com/2025-05-21-Medtronic-reports-strong-finish-to-its-fiscal-year-with-its-fourth-quarter-financial-results-announces-dividend-increase?utm_source=openai))  
- CVS: Still resetting medical-cost trend; value is there but more moving parts. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-SECOND-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx?utm_source=openai))  
- Intel: Big upside if foundry lands; risk/reward is more “speculative deep value” than classic value today. ([barrons.com](https://www.barrons.com/articles/intel-stock-price-panther-lake-chip-news-65d96fe2?utm_source=openai))  
- Micron: Great cycle, but not a classic value at this point in the upcycle. ([investors.micron.com](https://investors.micron.com/news-releases/news-release-details/micron-technology-inc-reports-results-third-quarter-fiscal-2025?utm_source=openai))  
- Berkshire: High quality, less mispriced. ([nasdaq.com](https://www.nasdaq.com/articles/berkshire-hathaway-q2-earnings-revenues-decline-year-over-year?utm_source=openai))  
- Alphabet/Meta: Reasonable valuations for giants, but capex overhang and market appreciation limit “value” upside vs. CAH. ([cnbc.com](https://www.cnbc.com/2025/02/04/alphabet-expects-to-invest-about-75-billion-in-capex-in-2025.html?utm_source=openai))

---

## Positioning Notes

- Sizing: For a diversified value portfolio, CAH could fit as a 3–5% core position, scaled up on pullbacks toward $145 and trimmed >$210 if rerating happens quickly.  
- Time horizon: 2–4 years to realize mix/medical improvements and multiple convergence.

---

## References and Primary Sources

- Cardinal Health FY25–FY26 results, guidance and segment details:  
  - Q4/FY25 results + FY26 guidance (EPS, FCF, capex, buybacks, shares) [newsroom.cardinalhealth.com] ([newsroom.cardinalhealth.com](https://newsroom.cardinalhealth.com/2025-08-12-Cardinal-Health-Reports-Fourth-Quarter-and-Fiscal-Year-2025-Results-and-Raises-Fiscal-Year-2026-Guidance?utm_source=openai))  
  - Q3 FY25 and raised FY25 outlook [newsroom.cardinalhealth.com] ([newsroom.cardinalhealth.com](https://newsroom.cardinalhealth.com/2025-05-01-Cardinal-Health-Reports-Third-Quarter-Fiscal-Year-2025-Results-and-Raises-Fiscal-Year-2025-Outlook?submitted=1&utm_source=openai))  
  - Q2 FY25 update (GI Alliance, ION acquisitions, interest outlook) [newsroom.cardinalhealth.com] ([newsroom.cardinalhealth.com](https://newsroom.cardinalhealth.com/2025-01-30-Cardinal-Health-Reports-Second-Quarter-Fiscal-Year-2025-Results-and-Raises-Fiscal-Year-2025-Outlook?utm_source=openai))  
  - Reuters specialty/pharma demand context [reuters.com] ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cardinal-health-forecasts-annual-profit-higher-end-prior-range-2025-01-14/?utm_source=openai))

- Market data (as of October 15, 2025):  
  - CAH, MCK, COR quotes [market data] 

- Peers and other candidates:  
  - Verizon 2025 guidance (EBITDA/EPS/FCF) [verizon.com] ([verizon.com](https://www.verizon.com/about/news/verizon-raises-financial-guidance-adjusted-ebitda-adjusted-eps-and-free-cash-flow?utm_source=openai))  
  - Pfizer 2025 guidance [pfizer.com] ([pfizer.com](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-full-year-2025-guidance-and-reaffirms-full?utm_source=openai))  
  - Medtronic FY25 results, dividend, separation plan [news.medtronic.com] ([news.medtronic.com](https://news.medtronic.com/2025-05-21-Medtronic-reports-strong-finish-to-its-fiscal-year-with-its-fourth-quarter-financial-results-announces-dividend-increase?utm_source=openai))  
  - CVS Q2 2025 and premium deficiency reserve [investors.cvshealth.com] ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-SECOND-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx?utm_source=openai))  
  - Intel 18A/Panther Lake progress [barrons.com; reuters.com; ft.com] ([barrons.com](https://www.barrons.com/articles/intel-stock-price-panther-lake-chip-news-65d96fe2?utm_source=openai))  
  - Micron FY25 trajectory and HBM [investors.micron.com; investing.com] ([investors.micron.com](https://investors.micron.com/news-releases/news-release-details/micron-technology-inc-reports-results-third-quarter-fiscal-2025?utm_source=openai))  
  - Berkshire cash/positioning [nasdaq.com] ([nasdaq.com](https://www.nasdaq.com/articles/berkshire-hathaway-q2-earnings-revenues-decline-year-over-year?utm_source=openai))  
  - Alphabet capex and AI infrastructure context [cnbc.com; fool.com] ([cnbc.com](https://www.cnbc.com/2025/02/04/alphabet-expects-to-invest-about-75-billion-in-capex-in-2025.html?utm_source=openai))  
  - Meta data center expansion [reuters.com] ([reuters.com](https://www.reuters.com/business/meta-commits-15-billion-ai-data-center-texas-2025-10-15/?utm_source=openai))

---

> Note: This is investment research and not investment advice. Please consider your objectives, risk tolerance, and constraints before acting.
